Omega Fund Management, LLC - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 17, 2026, for the 2025 Q4 period, Omega Fund Management, LLC held in its portfolio 11 assets valued at $286,520,062 (i.e. $286.52M).

The most valuable assets in the portfolio included: Nuvation Bio ($72.41M), BridgeBio Oncology Therapeutics Inc. ($41.19M), and Beta Bionics Inc. ($40.10M).

The chart below shows the top 10 valuable assets, and the table below shows the top 11 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in Omega Fund Management, LLC Portfolio

Nuvation Bio

BridgeBio Oncology Therapeutics Inc.

Beta Bionics Inc.

Bicara Therapeutics Inc.

Kestra Med Technologies Ltd

Upstream Bio Inc.

enGene Holdings Inc.

Alumis Inc.

Sana Biotechnology, Inc.

ImageneBio, Inc.

Omega Fund Management, LLC - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
Nuvation Bio	8081089	72406557	Common Stock Class A
BridgeBio Oncology Therapeutics Inc.	3289661	41186556	Common Stock
Beta Bionics Inc.	1316183	40104096	Common Stock
Bicara Therapeutics Inc.	2204650	37104260	Common Stock
Kestra Med Technologies Ltd	1373591	36427633	Common Stock
Upstream Bio Inc.	1326293	36008855	Common Stock
enGene Holdings Inc.	876357	7913504	Common Stock
Alumis Inc.	653223	6375456	Common Stock
Sana Biotechnology, Inc.	843750	3434063	Common Stock
ImageneBio, Inc.	455361	3141991	Common Stock
Replimune Group	248672	2417092	Common Stock